You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

348 Results
Drug
Other Name(s): Sylvant®
Mar 2025
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Palliative
Funding:
New Drug Funding Program
    Siltuximab - Multicentric Castleman’s Disease (MCD)
Mar 2025
Les programmes cliniques d’Action Cancer Ontario sont mis en œuvre en collaboration avec les cliniciens des Programmes régionaux de cancérologie en...
Drug
Other Name(s): Iressa®
Mar 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
Apr 2025
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatments of advanced or metastatic RET fusion-positive differentiated thyroid carcinoma (DTC); and unresectable advanced or metastatic RET-mutant medullary thyroid cancer (MTC)
Apr 2025
Guidelines and Advice
Jan 2016
A variety of screening tools and resources are available to support the screening activities of primary care providers, nurses and specialists.
Statistical Reports

Pages